COA ↓

Product

COA Doc

SYN-2631

99.0% Purity SYN-2631 Research Grade HPLC Verified

VIP (Vasoactive Intestinal Peptide)

Vasoactive Intestinal Peptide · Research Grade

Select Strength — 10mg

$220.00

C₁₄₇H₂₃₇N₄₃O₄₃S MW: 3326.79 g/mol CAS: 40077-57-4

Out of Stock

Notify me when back in stock

For in vitro laboratory research use only. Not for human consumption, diagnostic, or therapeutic use.

Certificate of Analysis

BATCH VERIFICATION

Every batch independently tested by accredited third-party laboratory. Full COA available on request.

Current Batch

HPLC Purity

Lot Number SYN-2631-VIP

Test Date

Labeled 98.2%

Actual 98.2%

HPLC Purity

Lot Number SYN-2530-VIP

Test Date

Labeled 98.2%

Actual 98.5%

Research Data

KEY FINDINGS

🧬

FDA Breakthrough Therapy (Aviptadil)

Aviptadil (synthetic VIP) received FDA Breakthrough Therapy Designation for COVID-19 respiratory failure

🔬

−62%

Cytokine Storm Suppression

TNF-α / IL-6 reduction in LPS-induced cytokine storm models — Gonzalez-Rey E et al.

✅

98.2%

HPLC-Verified Purity

Current batch SYN-2631, third-party accredited lab

❄️

24mo

Lyophilised Shelf Life

At −20°C sealed under inert atmosphere

Mechanisms of Action

IN VITRO RESEARCH OVERVIEW

Data presented from peer-reviewed in vitro studies. All findings are laboratory observations only.

🔬 Cytokine Storm Suppression

62% TNF-α Reduction — Treg Induction Mechanism

Gonzalez-Rey et al. characterised VIP's immunomodulatory mechanism in LPS-induced cytokine storm models, demonstrating 62% TNF-α and 58% IL-6 reduction with simultaneous induction of regulatory T-cells via VPAC1/VPAC2 signalling — establishing VIP as one of the most potent endogenous anti-inflammatory neuropeptides.

🔬 62–71% pro-inflammatory cytokine suppression — FDA Breakthrough Therapy Designation validates VIP's clinical anti-cytokine-storm potential.

PMID 16435759 — J. Clin. Invest.

62 %

Cytokine Storm Suppression via Treg Induction

VIP is a 28-amino-acid neuropeptide and potent anti-inflammatory agent that acts via VPAC1 and VPAC2 receptors to suppress pro-inflammatory cytokines, induce regulatory T-cells, and modulate the gut-immune axis — with the synthetic form (Aviptadil) receiving FDA Breakthrough Therapy Designation for COVID-19 ARDS.

Cytokine Suppression — VIP in LPS-Induced Storm Model

TNF-α reduction (VIP) −62%

IL-6 reduction (VIP) −58%

IL-12 reduction (VIP) −71%

Source: Gonzalez-Rey E et al., J. Clin. Invest., 2006

Analytical Data

PURITY VERIFICATION

Purity by Method — Batch SYN-2631-VIP

Specification	Value
CAS Number	40077-57-4
Molecular Formula	C₁₄₇H₂₃₇N₄₃O₄₃S
Molecular Weight	3326.79 g/mol
Purity (HPLC)	99.0%
Appearance	White lyophilised powder
Solubility	Soluble in water (1 mg/mL)
Storage	−20°C long-term / 2–8°C short-term
Shelf Life	24 months from production date
Research Grade	Yes — For In Vitro Use Only

62 %

TNF-α Reduction in LPS-Induced Cytokine Storm Model

VIP (TNF-α) −62%

VIP (IL-6) −58%

Control 0%

Comparative Activity Profile

VIP

Observed Adverse Indicators

20%

Transient facial flushing (IV)

low

12%

Nausea / GI discomfort (high dose)

low

Transient hypotension (IV)

moderate

Serious adverse events (Phase II)

low

⚠️ Theoretical Concern

FDA Breakthrough Status & Research Handling Notes

Aviptadil (synthetic VIP) carries FDA BT Designation and Phase II/III safety data from COVID-19 ARDS trials. Primary research consideration is stability — VIP is highly sensitive to light and temperature.

FDA Breakthrough Therapy Designation (Aviptadil) — Phase II/III safety data in acute respiratory failure
Endogenous neuropeptide produced in hypothalamus, enteric nervous system, and lung tissue
Transient vasodilation effects at higher doses — expected from VPAC receptor-mediated cAMP/PKA signalling
For in vitro laboratory research use only — not for human or veterinary administration

Peer-Reviewed Literature

RESEARCH CITATIONS

Journal of Clinical Investigation

Neuropeptide VIP Potently Induces Regulatory Dendritic Cells and T Cells

2006 Gonzalez-Rey E et al.

PMID 16435759 — View on PubMed

All citations refer to published peer-reviewed in vitro research. Data presented for scientific reference only. No claims made regarding human therapeutic use.